Analysed SKYE BIOSCIENCE INC (SKYE:NASDAQ) News Sources
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
02-04-2026
yahoo.com
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference
18-03-2026
marketbeat.com
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...
12-03-2026
yahoo.com
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
10-03-2026
yahoo.com
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
05-03-2026
yahoo.com
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
17-02-2026
yahoo.com
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
02-02-2026
yahoo.com
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
29-01-2026
yahoo.com
What is the current price of SKYE BIOSCIENCE INC (SKYE:NASDAQ)?
The current price of SKYE BIOSCIENCE INC (SKYE:NASDAQ) is $0.8251.
SKYE BIOSCIENCE INC (SKYE:NASDAQ) absolute price change since previous trading day?
The absolute price change of SKYE BIOSCIENCE INC (SKYE:NASDAQ) since the previous trading day is $0.0417.
SKYE BIOSCIENCE INC (SKYE:NASDAQ) percentage price change since previous trading day?
The percentage price change of SKYE BIOSCIENCE INC (SKYE:NASDAQ) since the previous trading day is 5.323%.
What is the most recent average sentiment score for SKYE BIOSCIENCE INC (SKYE:NASDAQ)?
The most recent average sentiment score for SKYE BIOSCIENCE INC (SKYE:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for SKYE BIOSCIENCE INC (SKYE:NASDAQ)?
The most recent sentiment for SKYE BIOSCIENCE INC (SKYE:NASDAQ) is .
SEC-8K** Filing Available For SKYE BIOSCIENCE INC (SKYE:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.